Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-07-11
2010-06-01
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S640000
Reexamination Certificate
active
07727967
ABSTRACT:
Compositions of matter for treating cancer patients are used to prevent or limit cardiotoxicity during or after treatment with anthracycline drugs, and to prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Preferred embodiments comprise a pharmaceutical composition comprising compounds having halogenated (or pseudo-halogenated) aryl groups, preferably halogenated (or pseudo-halogenated) arylcyanooximes or phenylcyanooximes and derivatives or analogs thereof, including those comprising —CL or —F, or other substituents on an aryl/phenyl ring. The preferred composition of arylcyanooxime(s) may be administered in a pharmaceutical composition also comprising at least one anthracycline compound, or may be administered separately from the at least one anthracycline compound.
REFERENCES:
patent: 3164524 (1965-01-01), Fand et al.
patent: 3170945 (1965-02-01), Schisla et al.
patent: 3234255 (1966-02-01), Rosinger et al.
patent: 3300376 (1967-01-01), Schisla et al.
patent: 3336199 (1967-08-01), Stolar et al.
patent: WO 98/51303 (1998-11-01), None
patent: WO 2005/007085 (2005-01-01), None
Goodman and Gilman's The Pharmacological Basis of Therapeutics. editors Joel G. Hardman and lee E. Limbird, published by The McGraw-Hill Companies, Inc., 2001, p. 54-56.
Bacq, et al.; “Successful Treatment of Acute Fascioliasis With Bithionol”Hepatologyp. 1; 1991.
“Drugs for Parasitic Infections”;The Medical Letter, Inc; pp. 1-12; Aug. 2004.
Olson, et al.; “Protection from Doxorubicin-Induced Cardiac Toxicity in Mice with a Null Allele of Carbonyl Reductase”Cancer Research63; 6002-6006; Oct. 15, 2003.
Aiken, et al.; “A Cell-Based Screen for Drugs to Treat Huntington's Disease”Neurobiology of Disease;16; 546-555; 2004.
Hawn, et al.; “Update on Hepatobiliary and Pulmonary Flukes [Abstract]”Current Infectious Disease Reports1999.
Minotti, et al.; “Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity”;The American Society for Pharmacology and Experimental Therapeuticsvol. 56, No. 2 185-229; 2004.
Forrest, et al.; “Human Carbonyl Reductase Overexpression in the Heard Adances of the Development of Doxorubicin-induced Cardiotoxicity in Transgenic Mice”;Cancer Research, 5158-5164; Sep. 15, 2000.
“Bithionol Product Information”;Sigma-Aldrich, Inc; 2 pages; May 24, 2005.
“2,2′-Sulfinyl-bis (4,6-dichlorophenol) Product Information”; 222.sigmaaldrich.com; May 24, 2005.
Tanaka, et al.; “An Unbiased Cell Morphology -Based Screen for New”, Biological Active Small Molecules;oS Biology, 0764-0776; May 2005.
Charlier, Jr. Henry A.
Gerasimchuk Nikolay
Boise State University
Goon Scarlett
Jiang Shaojia Anna
Pedersen Barbara S.
Pedersen Ken J.
LandOfFree
Cyanooxime inhibitors of carbonyl reductase and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyanooxime inhibitors of carbonyl reductase and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyanooxime inhibitors of carbonyl reductase and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4235292